The value of progression-free survival to patients with advanced-stage cancer (Q37947085)

25 August 2017

The value of progression-free survival to patients with advanced-stage cancer (English)

1 reference

25 August 2017

0 references

1

1 reference

25 August 2017

2

1 reference

25 August 2017

Anne Fleissig

3

1 reference

PubMed ID

22009075

25 August 2017

language of work or name

English

0 references

publication date

18 October 2011

1 reference

Nature Reviews Clinical Oncology

25 August 2017

1 reference

25 August 2017

9

1 reference

25 August 2017

1

1 reference

25 August 2017

41-47

1 reference

Reflections on medical oncology: 25 years of clinical trials--where have we come and where are we going?

25 August 2017

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.156

Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.156

Assessing the measure of a new drug: is survival the only thing that matters?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.156

American Society of Clinical Oncology Statement: Toward Individualized Care for Patients With Advanced Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.156

Bevacizumab for advanced breast cancer: all tied up with a RIBBON?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.156

When are "positive" clinical trials in oncology truly positive?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.156

Trials in palliative treatment--have the goal posts been moved?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.156

Big costs for little gain in ovarian cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.156

Biologically targeted cancer therapy and marginal benefits: are we making too much of too little or are we achieving too little by giving too much?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.156

How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.156

Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.156

Clinical benefit in oncology trials: is this a patient-centred or tumour-centred end-point?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.156

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.156

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.156

In the end what matters most? A review of clinical endpoints in advanced breast cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.156

Recommendations for the assessment of progression in randomised cancer treatment trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.156

When you look matters: the effect of assessment schedule on progression-free survival

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.156

Use of progression-free survival as a surrogate marker in oncology trials: some regulatory issues

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.156

Variability of lung tumor measurements on repeat computed tomography scans taken within 15 minutes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.156

Progression-free survival is a surrogate for survival in advanced colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.156

Evolving options for the treatment of metastatic breast cancer: progression-free survival as an endpoint

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.156

Clinical trial endpoints in ovarian cancer: report of an FDA/ASCO/AACR Public Workshop.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.156

Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.156

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.156

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.156

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.156

Potential withdrawal of bevacizumab for the treatment of breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.156

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.156

Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group tria

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.156

Maintenance therapy in advanced ovarian cancer: progression-free survival and clinical benefit.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.156

Maintenance therapy in non-small-cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.156

Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.156

Quality of life: a new perspective for cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.156

Patient-reported outcomes in drug safety evaluation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.156

Quality of life and/or symptom control in randomized clinical trials for patients with advanced cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.156

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.156

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.156

Progress in cancer care: the hope, the hype, and the gap between reality and perception

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.156

The ethical use of mandatory research biopsies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.156

Reasons given by patients for participating, or not, in Phase 1 cancer trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.156

Why do patients choose chemotherapy near the end of life? A review of the perspective of those facing death from cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.156

Cancer patient preferences for quality and length of life

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.156

End-of-life discussions, goal attainment, and distress at the end of life: predictors and outcomes of receipt of care consistent with preferences

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.156

The content and amount of information given by medical oncologists when telling patients with advanced cancer what their treatment options are. palliative chemotherapy and watchful-waiting

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.156

What oncologists believe they said and what patients believe they heard: an analysis of phase I trial discussions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.156

Use of electronic quality of life applications in cancer research and clinical practice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.156

The views of patients and the general public about expensive anti-cancer drugs in the NHS: a questionnaire-based study

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22009075

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRCLINONC.2011.156

1 reference

25 August 2017

1 reference

PubMed ID

22009075